JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, inclu…
Biotechnology
CN, Shanghai [HQ]
Ratios
6 Sheets · From 2023 to 2018Configuration
Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | 100.00 | 100.00 | - - | 29.37 | 40.33 | 50.74 | |
| Profit Margin | -126,798.14 | -11,549.46 | - - | -2,280.51 | -580.73 | -441.74 | |
| Operating Margin | -52,200.93 | -3,711.76 | - - | -2,505.82 | -478.49 | -454.17 | |
|
EPS Growth
|
- - | -1,252.78 | -29.47 | 86.04 | -17.05 | 9.22 | |
| EPS CNY | -72.00 | -974.00 | -1,261.00 | -176.00 | -206.00 | -187.00 | |
| Return on Assets (ROA) | -79.99 | -94.71 | -44.02 | -22.54 | -30.31 | -35.79 | |
| Return on Equity (ROE) | 87.04 | 67.20 | -48.51 | -25.17 | -35.94 | -45.61 | |
| Return on Invested Capital (ROIC) | 62.30 | -37.76 | -13.21 | -27.79 | -28.95 | -39.26 | |
| Solvency | |||||||
| Equity Ratio | - - | -100 | - - | - - | - - | - - | |
| Debt/Assets | 17.22 | 221.56 | 2.93 | 3.70 | 8.79 | 14.86 | |
| Debt/Equity | -18.74 | -157.20 | 3.23 | 4.13 | 10.42 | 18.93 | |
| Debt/EBITDA | 49.31 | 91.09 | 552.15 | 228.42 | 175.40 | 145.08 | |
|
Debt/Capitalization
|
-23.06 | 274.82 | 3.13 | 3.96 | 9.44 | 15.92 | |
| Long-Term Debt/Capitalization | -5.22 | 278.16 | 2.83 | 3.29 | 3.78 | 10.51 | |
| Interest Debt per Share CNY | 0.16 | 22.79 | 0.84 | 0.29 | 0.61 | 0.80 | |
| Debt Growth | - - | 32.53 | 58.90 | 18.97 | 89.84 | 14.21 | |
| Liquidity | |||||||
| Current Ratio | 76.04 | 212.79 | 1,116.82 | 952.76 | 477.80 | 403.63 | |
| Quick Ratio | 76.04 | 212.79 | 1,116.41 | 936.97 | 464.88 | 390.48 | |
| Cash Ratio | 59.33 | 207.52 | 1,109.75 | 922.27 | 445.04 | 380.35 | |
| Operating Cash Flow Ratio | - - | -100 | -100 | -200 | -100 | -100 | |
| Turnover | |||||||
| Inventory Turnover | - - | - - | - - | 69.27 | 216.50 | 246.24 | |
| Receivables Turnover | - - | - - | - - | - - | 2,746.50 | 762.83 | |
| Payables Turnover | - - | - - | - - | 30.18 | 122.19 | 2,619.67 | |
|
Asset Turnover
|
0.06 | 0.82 | - - | 0.99 | 5.22 | 8.10 | |
| Fixed Turnover | 0.28 | 2.70 | - - | 8.42 | 37.05 | 50.67 | |
| Coverage | |||||||
| Interest Coverage | -3,847.51 | - - | - - | -28,667.01 | -10,272.21 | -6,360.10 | |
| Asset Coverage | 100 | 500 | 2,200 | 1,400 | 600 | 400 | |
| Cash Flow Coverage (CFGR) | -181.00 | -12.75 | -235.39 | -487.21 | -218.71 | -124.98 | |
| EBITDA Coverage | -5,200 | - - | - - | -27,400 | -9,200 | -3,800 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -3.75 | -49.57 | -57.01 | -16.10 | -53.72 | -91.13 | |
|
Price/Earnings (P/E)
|
-2,664.15 | -201.72 | -175.41 | -621.14 | -186.16 | -109.73 | |
| Price/Earnings Growth (PEG) | - - | -0.16 | -5.95 | 7.22 | -10.92 | 11.90 | |
|
Price/Book (P/B)
|
-2,318.93 | -135.56 | 85.09 | 156.31 | 66.91 | 50.05 | |
| Price/Tangible Book (P/TB) | -2,318.93 | -135.56 | 85.09 | 156.31 | 66.91 | 50.05 | |
| Price/Sales (P/S) | 3,378,097.53 | 23,297.81 | - - | 14,165.16 | 1,081.10 | 484.73 | |
|
Price/Cash Flow (P/CF)
|
-6,837.22 | -676.16 | -1,118.17 | -777.35 | -293.48 | -211.52 | |
| Price/Free CF (P/FCF) | -4,829.90 | -439.17 | -757.57 | -687.77 | -256.71 | -204.05 | |
| Price/Operating CF (P/OCF) | -6,837.22 | -676.16 | -1,118.17 | -777.35 | -293.48 | -211.52 |